Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome

Transplantation

Volumn 61, Issue 2, 1996, Pages 224-228

  Eason, James D ^c,d   Pascual, Manuel ^a   Wee, Siewlin ^a   Farrell, Marylin ^a   Phelan, JoAnn ^a   Boskovic, Svetlan ^a   Blosch, Consuelo ^b   Mohler, Kendall M ^b   Cosimi, A Benedict ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b AMGEN INC   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 3; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL;

ACUTE DISEASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SYNDROME; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030025253     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601270-00011     Document Type: Article

References (31)

1. Beutler B, Mahoney J, LeTrang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985; 161: 984.
2. Steffen M, Ottman OG, Moore MAS. Simultaneous production of tumor necrosis factor alpha and lymphotoxin by normal T cells after induction with IL-2 and anti-T3. J Immunol 1988; 140: 2621.
3. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
4. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Transplantation 1990; 49: 697.
5. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon. N Engl J Med 1989; 320: 1420.
6. Toussaint C, DePauw L, Vereerstraeten P, Kinnaert P, Abramowicz D, Goldman M. Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation. Transplantation 1989; 48: 524.
7. Cosimi AB, Burton R, Colvin R, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535.
8. Maury CPJ, Teppo AM. Raised serum levels of cachectin/tumor necrosis factor-alpha in renal allograft rejection. J Exp Med 1987; 166: 1132.
9. McLaughlin PJ, Aikawa AA, Davies HM, et al. Evaluation of sequential plasma and urinary tumor necrosis factor-alpha levels in renal allograft recipients. Transplantation 1991; 51: 1225.
10. Blancho G, Moreau JF, Chabannes D, Chatenoud L, Soulillou JP. HILDA/LIF, GCSF, IL-1 beta, IL-6, and TNF-alpha production during acute rejection of human kidney allografts. Transplantation 1993; 56: 597.
11. Pizarro TT, Malinowska K, Kovacs EJ, Clancy J, Robinson JA, Piccinini LA. Induction of TNF alpha and TNF beta gene expression in rat cardiac transplants during allograft rejection. Transplantation 1993; 56: 399.
12. Imagawa DK, Millis JM, Olthoff KM, et al. The role of tumor necrosis factor in allograft rejection: I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990; 50: 219.
13. Noronha IL, Hartley B, Cameron JS, Waldherr R. Detection of IL-1 beta and TNF-alpha message and protein in renal allograft biopsies. Transplantation 1993; 55: 773.
14. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548.
15. Eason JD, Wee SL, Kawai T, et al. Inhibition of the effects of TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1994; 59: 300.
16. Eason JD, Wee SL, Kawai T, et al. Recombinant human dimeric tumor necrosis factor receptor (TNFR:Fc) as an immunosuppressive agent in renal allograft recipients. Transplant Proc 1995; 27: 554.
17. Wee SL, Boskovic S, Eason JD, Widmer MB, Cosimi AB. Preclinical study of a recombinant soluble tumor necrosis factor receptor: effect on immune response of renal allograft recipients. Transplant Proc 1995; 27: 411.
18. Ferran C, Dautry F, Merite S, et al. Anti-TNF modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994; 93: 2189.
19. Charpentier B, Hiesse C, Lantz O, et al. Evidence that anti-human tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997.
20. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68: 167.
21. Cohen DJ, Benvenisty AI, Cianci J, Hardy MA. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function. Am J Kidney Dis 1989; 14(suppl 2): 19.
22. Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262: 6951.
23. Christiansen NP, Skubitz KM, Nath K, et al. Nephrotoxicity of continuous intravenous infusion of recombinant IL-2. Am J Med 1988; 84: 1072.
24. Ault BH, Stapleton FB, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319: 1397.
25. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470.
26. Imagawa DK, Millis JM, Olthoff KM, et al. The role of TNF in allograft rejection: II. Evidence that antibody therapy against TNFa and LT enhances cardiac allograft survival in rats. Transplantation 1990; 50: 189.
27. Cavender DE, Edelbaum D, Ziff M. Endothelial cell activation induced by tumor necrosis factor and lymphotoxin. Am J Pathol 1989; 134: 551.
28. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor-beta and reversal by recombinant TNFa. J Exp Med 1987; 166: 991.
29. Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor. J Immunol 1988; 140: 531.
30. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive TNFa in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845.
31. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323.